BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:18 PM
 | 
Jun 28, 2010
 |  BC Extra  |  Clinical News

Astellas reports ASP1941 data

Astellas Pharma Inc. (Tokyo:4503) said all doses of once-daily oral ASP1941 significantly and dose-dependently reduced HbA1c from baseline to week 12 vs. placebo (p<0.001 for all),...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >